J&J's Daratumumab Shows Promise in Recovering Kidney Function in Light Chain Cast Nephropathy, Potentially Outperforming Plasma Exchange
A New Era in Treating Multiple Myeloma Complications
Light Chain Cast Nephropathy (LCCN), a complication of multiple myeloma, is a life-threatening condition that causes acute kidney injury (AKI). Plasma exchange, a procedure that mechanically removes harmful substances from the blood, has been commonly used to treat LCCN. However, its effectiveness in restoring kidney function has been debated. A clinical trial (NCT06483139) conducted jointly by Brigham and Women's Hospital and Janssen was designed to objectively compare the efficacy of the two treatments. Completed in June 2026, this trial will provide evidence to determine whether targeted antibody therapy is superior to mechanical filtration in preserving kidney function.
Mechanical Removal vs. Biological Targeted Therapy: A Comparison of Mechanisms
This study compares kidney recovery rates between patients undergoing mechanical filtration and those receiving the latest immunotherapeutic agents, using data from 549 actual patients. The comparison groups include patients who received plasma exchange, those who received Daratumumab-based therapy (e.g., Dara-CyBorD), and those who received non-Daratumumab-based therapy (e.g., CyBorD). Plasma exchange temporarily filters abnormal proteins from the blood, while Daratumumab directly targets the CD38 protein on myeloma cells, blocking the production of toxic light chain proteins. Through this comparative analysis, clinicians will be able to determine which approach – physical removal or immunological blockade – is more effective in alleviating kidney damage in patients with blood cancer.
Large-Scale Real-World Data to Inform Treatment Guidelines
To overcome the limitations of single-institution studies, this trial integrates large-scale real-world data (RWD) from multiple major medical institutions in the United States, enhancing its reliability. The primary endpoint is whether patients survive and regain kidney function within 90 days of LCCN diagnosis, and are able to discontinue renal replacement therapy (RRT). With the availability of data from a cohort of over 500 patients, a significant improvement in statistical significance is expected in this area of nephropathy treatment, which has been difficult to standardize due to small patient numbers and variations in prescription. If the kidney-protective efficacy of Daratumumab-based therapy is confirmed, clinical guidelines are likely to be revised to eliminate the need for invasive and costly plasma exchange.
Daratumumab's Commercial Dominance Strengthened in the Global Market
Janssen's Daratumumab (brand name: Darzalex) has established itself as a leading blockbuster drug in the global multiple myeloma market. Darzalex's global sales have grown rapidly from $11.67 billion in 2024 to $14.351 billion in 2025, driving the growth of the global multiple myeloma market, which is valued at approximately $27.8 billion. The completion of this trial will provide data that will solidify Daratumumab's position as a standard therapy not only for killing cancer cells but also for preventing life-threatening organ damage, such as kidney failure. This is expected to lead to increased prescription rates and further strengthen Johnson & Johnson's market leadership.
With the global multiple myeloma market valued at approximately $27.8 billion, the completion of this observational study (NCT06483139) will be a pivotal moment for Johnson & Johnson's Daratumumab (Darzalex), which recorded sales of $14.351 billion in 2025, to strengthen its dominance as a first-line therapy for patients with kidney complications. In the short term, it is expected that Daratumumab-based Dara-CyBorD therapy will become the new standard treatment guideline, replacing the high-cost plasma exchange, which has been the subject of ongoing debate regarding its efficacy. In the medium to long term, as the rapid light chain removal efficacy of Daratumumab, which targets CD38, is proven, it is expected to secure a strong clinical differentiation factor compared to Sanofi's competing drug, Isatuximab (Sarclisa). For researchers, it will provide clinical evidence to establish a standardized recovery prediction model for each stage of acute kidney injury (KDIGO 1-3) based on large-scale real-world data from 549 patients.
Source: ClinicalTrials.gov (api_ct)